This article summarizes a conversation with Trish Nettleship, Director, Social Media & Influence, UCB, Inc., about her company's approach to social media listening.
Pharma Marketing Ethics & Corporate Reputation Compendium: Bad, Devalued, Distrusted & Defensive Pharma
Welcome to The Pharma Marketing Ethics & Corporate Reputation Compendium, which is a catalog of articles, blog posts, podcasts, and surveys about the pharmaceutical industry's marketing practices viz-a-viz ethics and its corporate reputation.
This article is a summary of a study that evaluated claims in consumer-targeted television drug advertising against pharmacological evidence in order to determine the frequency of false or misleading claims made in these ads.
This article reviews social media breakthroughs by Boehringer, AstraZeneca, & Janssen.
Do pharma C-level executives really need to use social media directly or is it adequate that they see the value of social media within their organizations and ensure that others have the experience necessary to manage social media? This article attempts to answer that question with the help of Alexandra Fulford, an independent pharmaceutical industry strategy consultant who has worked with several pharmaceutical companies developing and running digital and social media training programs and workshops.
Ethicists identify six 'principles of influence' that are key to the drug industry’s routine marketing strategies, which rely on the illusion that the industry is a generous avuncular partner to physicians.
The Pharma Digital Media Adoption Curve illustrates how the drug industry is overcoming the regulatory hurdles to adopting emerging digital technology and especially social media.
As with Web sites in the early days, it is difficult today for users of mobile health apps to be assured that the apps are reliable, accurate, based on valid information, and adequately safeguard users' information. In many ways, we are living through another digital
You know the Tale of Two Cities. This article, however, tells the Tale of Two Books: Bad Pharma, a 430-page book by Ben Goldacre, a British physician, whose previous book, Bad Science, was a best seller in the non-fiction realm and the much smaller 123-page book Devalued and Distrusted by John L. LaMattina, former president of research and develop at Pfizer.
Jennifer Miller, a fellow at the Edmund J Safra Center for Ethics at Harvard University and president of Bioethics International, a non-profit that advises educational programs on ethical issues on medicine and healthcare, is trying to develop the industry equivalent of a 'Good Housekeeping Seal of Approval.' This article summarizes her ideas and presents opinions of several naysayers.